Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation.

Exposure to dextran sulfate sodium (DSS) induces acute colitis, which is normally resolved after DSS removal. To study chronicity, mice are typically subjected to three to five cycles of weekly DSS exposures, each followed by a 1- to 2-wk rest period. Here, we describe a novel and convenient way of inducing chronic, progressive colitis by a single exposure to DSS. C57BL/6 mice exposed to DSS for 5 days developed acute colitis that progressed to severe chronic inflammation. The plasma haptoglobin levels remained high during the chronic phase, showing that the inflammation was active. Surprisingly, the mice regained their original weight along with the progression of colitis, and the only apparent symptom was loose feces. Histopathological changes 4 wk after DSS removal were dense infiltrates of mononuclear cells, irregular epithelial structure, and persistent deposits of collagen. A progressive production of the cytokines IL-1beta, IL-12 p70, and IL-17 correlated with the extensive cellular infiltration, whereas high IFN-gamma production was mainly found late in the chronic phase. Similar to C57BL/6 mice, BALB/c mice exposed to 5 days of DSS developed acute colitis as previously described. The acute colitis was accompanied by elevated plasma levels of haptoglobin and increased colonic levels of IL-1alpha/beta, IL-6, IL-18, and granulocyte colony-stimulating factor. However, soon after DSS removal, BALB/c mice recovered and were symptom free within 2 wk and completely recovered 4 wk after DSS removal in terms of histopathology, haptoglobin levels, and local cytokine production. In summary, these data stress the effect of genetic background on the outcome of DSS provocation. We believe that the present protocol to induce chronic colitis in C57BL/6 mice offers a robust model for validating future therapies for treatment of inflammatory bowel disease.

[1]  D. Podolsky,et al.  Inflammatory bowel disease. , 2002, The New England journal of medicine.

[2]  J. Stockman Anti-Interleukin-12 Antibody for Active Crohn's Disease , 2006 .

[3]  R. Rerko,et al.  In vivo production and function of IL-12 p40 homodimers. , 1997, Journal of immunology.

[4]  H. Stein,et al.  Cellular localization of procollagen gene transcripts in inflammatory bowel diseases. , 1992, Gastroenterology.

[5]  K. Kyokane,et al.  Increased mucosal production of granulocyte colony‐stimulating factor is related to a delay in neutrophil apoptosis in Inflammatory Bowel disease , 1999, Journal of gastroenterology and hepatology.

[6]  H. Cooper,et al.  Clinicopathologic study of dextran sulfate sodium experimental murine colitis. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[7]  F. Annunziato,et al.  Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. , 1997, The American journal of pathology.

[8]  J. Willis,et al.  A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-kappa B. , 2003, Gastroenterology.

[9]  G. Fantuzzi,et al.  IL-1 beta -converting enzyme (caspase-1) in intestinal inflammation. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[10]  C. Elson,et al.  Kinetics of cytokine expression during healing of acute colitis in mice. , 1996, The American journal of physiology.

[11]  M. Büchler,et al.  Characterisation of Acute Murine Dextran Sodium Sulphate Colitis: Cytokine Profile and Dose Dependency , 2000, Digestion.

[12]  P. Sime,et al.  Differences in the fibrogenic response after transfer of active transforming growth factor-beta1 gene to lungs of "fibrosis-prone" and "fibrosis-resistant" mouse strains. , 2002, American journal of respiratory cell and molecular biology.

[13]  C. Moskaluk,et al.  IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. , 1998, Journal of immunology.

[14]  J. Sundberg,et al.  Differential susceptibility of inbred mouse strains to dextran sulfate sodium-induced colitis. , 1998, The American journal of physiology.

[15]  G. Churchill,et al.  Genetic analysis of susceptibility to dextran sulfate sodium-induced colitis in mice. , 1999, Genomics.

[16]  K. Geboes,et al.  Influence of treatment on morphological features of mucosal inflammation , 2002, Gut.

[17]  M. Daperno,et al.  Crohn's disease: monitoring disease activity , 2003 .

[18]  W. Kuis,et al.  Peripheral Blood Mononuclear Cells Cytokines in a Single Sample of Stimulated Simultaneous Detection of 15 Human , 2002 .

[19]  B. Vainer,et al.  Upregulation of Interleukin-12 and -17 in Active Inflammatory Bowel Disease , 2003, Scandinavian journal of gastroenterology.

[20]  J. Ni,et al.  Effects of dextran sulphate sodium on intestinal epithelial cells and intestinal lymphocytes. , 1996, Gut.

[21]  S. K. Lim,et al.  Haptoglobin, an inflammation-inducible plasma protein , 2001, Redox report : communications in free radical research.

[22]  T. Mayumi,et al.  Involvement of CD4+ T cells in the development of dextran sulfate sodium-induced experimental colitis and suppressive effect of IgG on their action. , 1998, General pharmacology.

[23]  M. Abe,et al.  Cytokine , 2020, Bone Marrow Transplantation.

[24]  G. Morrone,et al.  Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. , 1997, Gastroenterology.

[25]  R. Pounder,et al.  The value of rectal biopsy in distinguishing self-limited colitis from early inflammatory bowel disease. , 1987, The Quarterly journal of medicine.

[26]  L. Chauvelot‐Moachon,et al.  Network of inflammatory cytokines and correlation with disease activity in ulcerative colitis , 1998, American Journal of Gastroenterology.

[27]  J. Pucilowska,et al.  Fibrogenesis. IV. Fibrosis and inflammatory bowel disease: cellular mediators and animal models. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[28]  R. Willén,et al.  Histologic and colonoscopic assessment of disease extension in ulcerative colitis. , 1987, Scandinavian journal of gastroenterology.

[29]  M. Neurath,et al.  Anti-interleukin-12 antibody for active Crohn's disease. , 2004, The New England journal of medicine.

[30]  M. Seo,et al.  Correlation between endoscopic severity and the clinical activity index in ulcerative colitis. , 1998 .

[31]  J Wagner,et al.  Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. , 2000, Immunity.

[32]  W. Falk,et al.  Neutralization of tumour necrosis factor (TNF) but not of IL‐1 reduces inflammation in chronic dextran sulphate sodium‐induced colitis in mice , 1997, Clinical and experimental immunology.

[33]  M. Capobianchi,et al.  Spontaneous release of interferon gamma by intestinal lamina propria lymphocytes in Crohn's disease. Kinetics of in vitro response to interferon gamma inducers. , 1991, Gut.

[34]  M. Daperno,et al.  Review article: Crohn's disease: monitoring disease activity. , 2003, Alimentary pharmacology & therapeutics.

[35]  M. Leach,et al.  Characterization of chemokines and chemokine receptors in two murine models of inflammatory bowel disease: IL‐10– / – mice and Rag‐2– / – mice reconstituted with CD4+CD45RBhigh T cells , 2001, European journal of immunology.

[36]  D. Sacks,et al.  The immunology of susceptibility and resistance to Leishmania major in mice , 2002, Nature Reviews Immunology.

[37]  R. Riddell,et al.  Morphologic criteria applicable to biopsy specimens for effective distinction of inflammatory bowel disease from other forms of colitis and of Crohn's disease from ulcerative colitis. , 1999, Scandinavian journal of gastroenterology.

[38]  H. Kitagawa,et al.  Involvement of interleukin-1 in the development of ulcerative colitis induced by dextran sulfate sodium in mice. , 1998, Cytokine.

[39]  C. Smith,et al.  Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. , 1986, Gut.

[40]  J. Belaiche,et al.  Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. , 1994, Gut.

[41]  A Price,et al.  Observer variation and discriminatory value of biopsy features in inflammatory bowel disease. , 1994, Gut.

[42]  R. Blumberg,et al.  The Expression of IL-12 p40 and Its Homologue, Epstein-Barr Virus-Induced Gene 3, in Inflammatory Bowel Disease , 2001, Inflammatory bowel diseases.

[43]  S. Kitajima,et al.  Histological analysis of murine colitis induced by dextran sulfate sodium of different molecular weights. , 2000, Experimental animals.

[44]  R. Sartor,et al.  Mucosal injury and inflammation in a model of chronic granulomatous colitis in rats. , 1993, Gastroenterology.

[45]  M. Kindy,et al.  Increased serum amyloid a levels reflect colitis severity and precede amyloid formation in IL-2 knockout mice. , 2000, Cytokine.

[46]  S. Kitajima,et al.  Tissue distribution of dextran sulfate sodium (DSS) in the acute phase of murine DSS-induced colitis. , 1999, The Journal of veterinary medical science.

[47]  A. Levine,et al.  Interleukin 4 in inflammatory bowel disease and mucosal immune reactivity. , 1996, Gastroenterology.

[48]  C. Xian,et al.  Expression of B7 costimulatory molecules by cells infiltrating the colon in experimental colitis induced by oral dextran sulfate sodium in the mouse , 2001, Journal of gastroenterology and hepatology.

[49]  E. Bloemena,et al.  Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines , 1998, Clinical and experimental immunology.

[50]  P. Simon,et al.  Role of interleukin 1 in inflammatory bowel disease--enhanced production during active disease. , 1990, Gut.

[51]  C. Elson,et al.  Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. , 1994, Gastroenterology.

[52]  R. Kastelein,et al.  Novel IL-12 family members shed light on the orchestration of Th1 responses , 2003, Trends in Immunology.

[53]  M. Neurath,et al.  Antibodies to interleukin 12 abrogate established experimental colitis in mice , 1995, The Journal of experimental medicine.

[54]  I. Forgacs GASTROENTEROLOGY , 1988, The Lancet.

[55]  G. Fantuzzi,et al.  IL-1β-converting enzyme (caspase-1) in intestinal inflammation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[56]  I. Kushner,et al.  Acute-phase proteins and other systemic responses to inflammation. , 1999, The New England journal of medicine.

[57]  A. Andoh,et al.  Increased expression of interleukin 17 in inflammatory bowel disease , 2003, Gut.

[58]  A. Gurney,et al.  Interleukin-23 Promotes a Distinct CD4 T Cell Activation State Characterized by the Production of Interleukin-17* , 2003, The Journal of Biological Chemistry.

[59]  R. Farmer,et al.  The long-term outcome in Crohn's disease , 1987, Diseases of the colon and rectum.

[60]  Yaping Chen,et al.  Insights from mouse models of colitis , 2000, Journal of leukocyte biology.

[61]  N. Nieto,et al.  Experimental Colitis Induced by Trinitrobenzenesulfonic Acid (An Ultrastructural and Histochemical Study) , 1999, Digestive Diseases and Sciences.